Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-02-06

Clinical Trial Update: Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC) [Phase 2]

View source ↗

Summary

A completed Phase 2 trial (DAPAVASC) assesses the vascular effects of dapagliflozin in patients with chronic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FARXIGA (dapagliflozin)

Snippet

Sponsor: University Hospital, Rouen | Conditions: Renal Insufficiency, Chronic | Phase 2 | Status: COMPLETED